ASCO 2020 | JAVELIN Bladder 100: avelumab maintenance

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives us an update on the JAVELIN Bladder 100 study (NCT02603432) in urothelial carcinoma. This study that compared maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).